Home / News
Recent Updates
PROTEUS Supports Perioperative Apalutamide Plus ADT for High-Risk Prostate Cancer
What if adding therapy before and after surgery could improve outcomes in high-risk prostate cancer? PROTEUS evaluated perioperative apalutamide plus ADT and demonstrated improvements in pathologic response and metastasis-free survival.
June 1, 2026
All FDA Approvals
All Cancer Types Endometrial Cancer Hematologic Malignancies Leukemia Lymphoma Multiple Myeloma Non-Small Cell Lung Cancer Prostate Cancer
All Diagnostics + Biomarkers Screening
All Therapeutic Approaches Chemotherapy Immunotherapy Targeted Therapy

What are you looking for?

Popular Searches

Oncology Practice Management Navigation